Active and passive immunization against Clostridium difficile diarrhea and colitis

Vaccine

Volumn 22, Issue 7, 2004, Pages 848-856

  Giannasca, Paul J ^a   Warny, Michel ^a  

^a Acambis   (United States)

Author keywords

Clostridium difficile; Immunity; Vaccination

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; ANTIBIOTIC AGENT; ANTITOXIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CHOLERA TOXIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; EXOTOXIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METRONIDAZOLE; POLYCLONAL ANTIBODY; VANCOMYCIN;

ACTIVE IMMUNIZATION; AGE; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; COMMENSALISM; CONFERENCE PAPER; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG SAFETY; EXPOSURE; FLUID INTAKE; HOSPITAL INFECTION; HOST; HUMAN; IMMUNITY; IMMUNOGENICITY; INCIDENCE; INDUSTRIALIZATION; INTESTINE FLORA; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENICITY; PRIORITY JOURNAL; PROVOCATION TEST; RECURRENT DISEASE; RISK FACTOR; TOXIN STRUCTURE;

EID: 0842303177     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.030     Document Type: Conference Paper

References (72)

1. Kelly C.P., Pothoulakis C., LaMont J.T. Clostridium difficile colitis. N. Engl. J. Med. 330:1994;257-262.
2. McFarland L.V., Mulligan M.E., Kwok R.Y., Stamm W.E. Nocosomial acquisition of Clostridium difficile infection. N. Eng. J. Med. 320:1989;204-210.
3. Kyne L., Hamel M.B., Polavaram R., Kelly C.P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34:2002;346-353.
4. Larson H.E., Barclay F.E., Honour P., Hill I.D. Epidemiology of Clostridium difficile in infants. J. Infect. Dis. 146:1982;727-733.
5. Viscidi R., Willey S., Bartlett J.G. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology. 81:1981;5-9.
6. Fekety R., Kim K.H., Brown D., Batts D.H., Cudmore M., Silva J. Jr. Epidemiology of antibiotic associated colitis isolation of Clostridium difficile from the hospital environment. Am. J. Med. 70:1981;906-908.
7. Kim K.H., Fekety R., Batts D.H., Brown D., Cudmore M., Silva J. Jr.et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J. Infect. Dis. 143:1981;42-50.
8. Samore M.H., Degirolami P.C., Tlucko A., Lichtenberg D.A., Melvin Z.A., Karchmer A.W. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin. Infect. Dis. 18:1994;181-187.
9. Teasley D.G., Gerding D.N., Olson M.M., Peterson L.R., Gebhard R.L., Schwartz M.J.et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet. 2:1983;1043-1046.
10. McFarland L.V., Surawicz C.M., Greenberg R.N., Fekety R., Elmer G.W., Moyer K.A.et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 271:1994;1913-1918.
11. Wilcox M.H., Fawley W.N., Settle C.D., Davidson A. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J. Hosp. Infect. 38:1998;93-100.
12. Tasteyre A., Barc M.-C., Collignon A., Boureau H., Karjalainen T. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect. Immun. 69:2001;7937-7940.
13. Calabi E., Calabi F., Phillips A.D., Fairweather N.F. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect. Immun. 70:2002;5770-5778.
14. Waligora A.-J., Hennequin C., Mullany P., Bourlioux P., Collignon A., Karjalainen T. Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect. Immun. 69:2001;2144-2153.
15. von Eichel-Streiber C., Boquet P., Sauerborn M., Thelestam M. Large clostridial cytotoxins - a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol. 4:1996;375-382.
16. Warny M, Kelly CP. Pathogenicity of Clostridium difficile toxins. In: Hecht G, editor. Microbial Pathogenesis and the Intestinal Epithelial Cell. Washington, DC: ASM Press; 2003. p. 503-24.
17. von Eichel-Streiber C., Warfolomeow I., Knautz D., Sauerborn M., Hadding U. Morphological changes in adherent cells induced by Clostridium difficile toxins. Biochem. Soc. Trans. 19:1991;1154-1160.
18. Tucker K.D., Carring P.F., Wilkins T.D. Toxin A of Clostridium difficile is a potent cytotoxin. J. Clin. Microbiol. 28:1990;869-871.
19. Qa'Dan M., Spyres L.M., Ballard J.D. pH-induced conformational changes in Clostridium difficile toxin B. Infect. Immun. 68:2000;2470-2474.
20. Barth H., Pfeifer G., Hofmann F., Maier E., Benz R., Aktories K. Low pH-induced formation of ion channels by Clostridium difficile toxin B in target cells. J. Biol. Chem. 276:2001;10670-10676.
21. Just I., Selzer J., Wilm M., von Eichel-Streiber C., Mann M., Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature. 375:1995;500-503.
22. Just I., Wilm M., Selzer J., Rex G., von Eichel-Streiber C., Mann M.et al. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J. Biol. Chem. 270:1995;13932-13936.
23. Kurtz C.B., Cannon E.P., Brezzani A., Pitruzzello M., Dinardo C., Rinard E.et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. J. Antimicrob. Chemother. 45:2001;2340-2347.
24. Lyerly DM, Lockwood DE, Richardson SH, Wilkins TD. Biological effects of toxins A and B of Clostridium difficile. Infect Immun 1982;35:1147-50.
25. Lyerly D.M., Saum K.E., MacDonald D.K., Wilkins T.D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 47:1985;349-352.
26. Chang J., Rohwer R.G. Clostridium difficile infection in adult hamsters. Lab. Anim. Sci. 41:1991;548-552.
27. Chaves-Olarte E., Low P., Freer E., Norlin T., Weidmann M., von Eichel-Streiber C.et al. A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins. J. Biol. Chem. 274:1999;11046-11052.
28. Alfa M.J., Kabani A., Lyerly D., Moncrief S., Neville L.M., Al-Barrak A.et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38:2000;2706-2714.
29. Johnson S., Kent S.A., O'Leary K.J., Merrigan M.M., Sambol S.P., Peterson L.R.et al. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann. Intern. Med. 135:2001;434-438.
30. Limaye A.P., Turgeon D.K., Cookson B.T., Fritsche T.R. Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile. J. Clin. Microbiol. 38:2000;1696-1697.
31. Riegler M., Sedivy R., Pothoulakis C., Hamilton G., Zacherl J., Bischof G.et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J. Clin. Invest. 95:1995;2004-2011.
32. Savidge T.C., Pan W.H., Newman P., O'Brien M., Anton P.M., Pothoulakis C. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology. 125:2003;413-420.
33. Fernie D.S., Thompson R.O., Batty I., Walker P.D. Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev. Biol. Stand. 53:1983;325-332.
34. Kim P.H., Iaconis J.P., Rolfe R.D. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 55:1987;2984-2992.
35. Libby J.M., Jortner B.S., Wilkins T.D. Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect. Immun. 36:1982;822-829.
36. Torres J.F., Lyerly D.M., Hill J.E., Monath T.P. Evaluation of formalin-inactivated Clostridium difficile vaccine administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63:1995;4619-4627.
37. Giannasca P.J., Zhang Z.X., Lei W., Boden J.A., Giel M.A., Monath T.P.et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect. Immun. 67:1999;527-538.
38. Price S.B., Phelps C.J., Wilkins T.D., Johnson J.L. Cloning of the carbohydrate-binding portion of the toxin A gene of Clostridium difficile. Curr. Microbiol. 16:1987;55-60.
39. Lyerly D.M., Johnson J.L., Frey S.M., Wilkins T.D. Vaccination against lethal Clostridium difficile enterocolitis with a nontoxic recombinant peptide of toxin A. Curr. Microbiol. 21:1990;29-32.
40. Lyerly D.M., Phelps C.J., Toth J., Wilkins T.D. Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect. Immun. 54:1986;70-76.
41. Ward SJ, Douce G, Dougan G, Wren BW. Local and systemic antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun 1999;67:5124-32.
42. Ward S.J., Douce G., Dougan G., Wren B.W. Delivery of non-toxic fragments of Clostridium difficile toxin A to the mucosal immune system. Rev. Med. Microbiol. 8:1997;S34-S36.
43. Ward S.J., Douce G., Figueiredo D., Dougan G., Wren B.W. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect. Immun. 67:1999;2145-2152.
44. Ryan E.T., Butterton J.R., Smith R.N., Carroll P.A., Crean T.I., Calderwood S.B. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect. Immun. 65:1997;2941-2949.
45. Korhonen H., Marnila P., Gill H.S. Bovine milk antibodies for health. Br. J. Nutr. 84:2000;S135-S146.
46. Kelly C.P., Pothoulakis C., Vavva F., Castagliuolo I., Bostwick E.F., O'Keane J.C.et al. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob. Agents Chemother. 40:1996;373-379.
47. Lyerly D.M., Bostwick E.F., Binion S.B., Wilkins T.D. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect. Immun. 59:1991;2215-2218.
48. Kink J.A., Williams J.A. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 66:1998;2018-2025.
49. Allo M., Silva J. Jr., Fekety R., Rifkin G.D., Waskin H. Prevention of clindamycin-induced colitis in hamsters by Clostridium sordellii antitoxin. Gastroenterology. 76:1979;351-355.
50. Corthier G., Muller M.C., Wilkins T.D., Lyerly D., L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect. Immun. 59:1991;1192-1195.
51. Kelly C.P., Pothoulakis C., Orellana J., LaMont J.T. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology. 102:1992;35-40.
52. Delacroix D.L., Malburny G.N., Vaerman J.P. Hepatobiliary transport of plasma IgA in the mouse: contribution to clearance of intravascular IgA. Eur. J. Immunol. 15:1985;893-899.
53. Vaerman J.P., Langendries A. Hepatobiliary transport of IgA in the golden Syrian hamster (Mesocricetus auratus). Immunol. Lett. 55:1997;19-26.
54. Hecht G., Koutsouris A., Pothoulakis C., LaMont J.T., Madara J.L. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology. 102:1992;416-423.
55. Hecht G., Pothoulakis C., LaMont J.T., Madara J.L. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J. Clin. Invest. 82:1988;1516-1524.
56. Corthier G., Muller M.C., Elmer G.W., Lucas F., Dubos-Ramare F. Interrelationships between digestive proteolytic activities and production and quantitation of toxins in pseudomembranous colitis induced by Clostridium difficile in gnotobiotic mice. Infect. Immun. 57:1989;3922-3927.
57. Kim P.H., Rolfe R.D. Characterization of protective antibodies in hamsters immunized against Clostridium difficile toxins A and B. Microb. Ecol. Health Dis. 2:1989;47-59.
58. Viscidi R., Laughon B.E., Yolken R., Bo-Linn P., Moench T., Ryder R.W.et al. Serum antibody response to toxins A and B of Clostridium difficile. J. Infect. Dis. 148:1983;93-100.
59. Kelly C.P., Lamont J.T. Clostridium difficile infection. Annu. Rev. Med. 49:1998;375-390.
60. Aronsson B., Grantsrom M., Mollby R., Nord C.E. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection. 13:1985;97-101.
61. Johnson S., Sypura W.D., Gerding D.N., Ewing S.L., Janoff E.N. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect. Immun. 63:1995;3166-3173.
62. Leung D.Y., Kelly C.P., Boguniewicz M., Pothoulakis C., LaMont J.T., Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J. Pediatr. 118:1991;633-637.
63. Warny M., Vaerman J.P., Avesani V., Delmée M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect. Immun. 62:1994;384-389.
64. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:2000;390-397.
65. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 357:2001;189-193.
66. Kotloff K.L., Wasserman S.S., Losonsky G.A., Thomas W., Nichols R., Edelman R.et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect. Immun. 69:2001;988-995.
67. Aboudola S., Kotloff K.L., Kyne L., Warny M., Kelly E.C., Sougioultzis S.et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect. Immun. 71:2003;1608-1610.
68. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo, Pothoulakis C, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile associated diarrhea, submitted for publication.
69. Beales I.L. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut. 51:2002;456.
70. Salcedo J., Keates S., Pothoulakis C., Warny M., Castagliuolo I., LaMont J.T.et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 41:1997;366-370.
71. Warny M., Denie C., Delmee M., Lefebvre C. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta. Clin. Belg. 50:1995;36-39.
72. Kelly C.P., Chetham S., Keates S., Bostwick E.F., Roush A.M., Castagliuolo I.et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob. Agents Chemother. 41:1997;236-241.